Inex Pharmaceuticals Corporation
Burnaby, BC
Company Overview
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. INEX's strategy has been to develop technology capable of making anti-cancer drugs more effective and reduce their side-effects, thus giving these drugs a competitive advantage in the marketplace. The basic approach has been to encapsulate the drugs in a lipid envelope that is carried through the bloodstream and delivered to disease sites where the drugs are released to carry out their therapeutic action.
The delivery technology, called Transmembrane Carrier System (TCS), has led to the development of INEX's lead product, Onco TCS. Onco TCS has completed a pivotal Phase II/III clinical trial at leading medical centers across North America as a treatment for relapsed aggressive non-Hodgkin's lymphoma. Onco TCS is also being evaluated in nine additional Phase II clinical trials for the treatment of small cell lung cancer, Hodgkins disease, relapsed pediatric malignancies, acute lymphoblastic leukemia and in combination therapy for both first- line aggressive non-Hodgkins lymphoma and relapsed non- Hodgkins lymphoma.
INEX has expanded its application of the TCS technology to the chemotherapeutic drugs, Topotecan and Vinorelbine. Topotecan TCS is currently being developed in partnership with GlaxoSmithKline. The drug is expected to enter clinical trials in 2003. Vinorelbine TCS, the third targeted chemotherapy product is in preclinical development.
INEX is continuing its evaluation of other chemotherapeutic drugs that have characteristics likely to be improved by encapsulation in the TCS delivery technology.
INEX's second technology platform is called OligoVax and is based on lipid-encapsulated oligonucleotides. When used in combination with specific disease markers (antigens), OligoVax has the potential to activate the immune system against various diseases. This technology can be used to develop treatment for cancer and infectious diseases.
INEX is traded on The Toronto Stock Exchange under the symbol IEX.
Company Information
Physical Address
200-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
CA
Mailing Address
200-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
CA
Additional Details
Legal Name: Inex Pharmaceuticals Corporation
Number of Employees: 187
CA
INEX has developed a commercially suitable proprietary drug delivery system, called Transmembrane Carrier System (TCS) that optimizes delivery of intravenous drugs to tumour sites. TCS encapsulates chemotherapeutics in a lipid envelope, carries them through the bloodstream and releases them at tumour sites to ensure maximal activity. The TCS is capable of increasing the therapeutic index of anticancer drugs by decreasing drug toxicity and increasing drug efficacy.
INEX is also developing technology based on lipid-encapsulated oligonucleotides for use in combination with various disease- markers called antigens. OligoVax has the potential to activate the immune system against various disease conditions, including cancer and infectious diseases.
Contacts
Ian Mortimer
Title: Vice President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
David Main
Title: President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Pieter Cullis
Title: Vice President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Products
- Oligovax
-
Onco Tcs
Onco TCS is a proprietary drug comprised of the widely used, off- patent, chemotherapeutic drug vincristine encapsulated in INEXs proprietary drug delivery system, Transmembrane Carrier System. Onco TCS has completed a pivotal Phase II/III clinical trial for relapsed aggressive non-Hodgkin's lymphoma and will be filing for marketing approval with the United States Food & Drug Administration in 2003.
-
Topotecan Tcs
Topotecan TCS is being developed with GlaxoSmithKline (GSK). The product utilizes GSKs proprietary compound, topotecan hydrochloride, as the encapsulated anticancer drug in the TCS technology. The product, currently in preclinical development, is anticipated to enter phase I clinical trials in 2003.
-
Vinorelbine Tcs
Vinorelbine TCS is the encapsulation of the off-patent chemotherapeutic drug, vinorelbine, in the TCS technology. The product is currently in preclinical development.
NAICS Categories
Additional Information
325410